Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), and Sumitomo Dainippon Pharma Co., Ltd., today announced that a new drug application for TWYMEEG® Tablets 500mg3 (Imeglimin hydrochloride), for the treatment of type 2 diabetes, was approved in Japan on June 23.